Figure 4 Key results of the ARTS,...

Figure 4

$Key results of the ARTS, ARTS-HF, and ARTS-DN Phase II studies. *Significant (P ≤ 0.001); #Nominal statistical significance in the finerenone 10–20 mg group (hazard ratio = 0.56, 95% confidence interval 0.35; 0.90, P = 0.02). CV, cardiovascular; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; T2D, Type 2 diabetes; UACR, urine albumin-to-creatinine ratio.$

Key results of the ARTS, ARTS-HF, and ARTS-DN Phase II studies. *Significant (P ≤ 0.001); ^#Nominal statistical significance in the finerenone 10–20 mg group (hazard ratio = 0.56, 95% confidence interval 0.35; 0.90, P = 0.02). CV, cardiovascular; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; T2D, Type 2 diabetes; UACR, urine albumin-to-creatinine ratio.

This Feature Is Available To Subscribers Only